sEVs from KRAS-mutated colon tumors enhance invasiveness of recipient cells in vitro by transferring tumor promotors, such as mutant KRAS [83], endodermal growth factor receptor (EGFR), and integrins to KRAS wildtype cells [84]. The gene discussed is KRAS; the disease is neoplasm.